Black, Jonathan D <br/><br/>
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.  [electronic resource] 

 -  British journal of cancer  Sep 2015 
 - 1020-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2015.306  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Biomarkers, Tumor--genetics<br/>Cell Survival--drug effects<br/>Class I Phosphatidylinositol 3-Kinases<br/>Cystadenocarcinoma, Serous--drug therapy<br/>Female<br/>Gene Amplification<br/>Humans<br/>Mice<br/>Mutation<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Receptor, ErbB-2--genetics<br/>Trastuzumab--administration & dosage<br/>Uterine Neoplasms--drug therapy<br/>Xenograft Model Antitumor Assays